Human CXCL5/ENA-78 Antibody Summary
Ala37-Asn114
Accession # P42830
Applications
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Scientific Data
Chemotaxis Induced by CXCL5/ENA‑78 and Neutral-ization by Human CXCL5/ ENA‑78 Antibody. Recombinant Human CXCL5/ENA-78 (Catalog # 254-XB) chemo-attracts the BaF3 mouse pro-B cell line transfected with human CXCR2 in a dose-dependent manner (orange line). The amount of cells that migrated through to the lower chemotaxis chamber was measured by Resazurin (Catalog # AR002). Chemotaxis elicited by Recombinant Human CXCL5/ ENA-78 (30 ng/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Human CXCL5/ ENA-78 Polyclonal Antibody (Catalog # AB-254-PB). The ND50 is typically 4-16 µg/mL.
Reconstitution Calculator
Preparation and Storage
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: CXCL5/ENA-78
CXCL5, also known as epithelial cell-derived-neutrophil-activating-peptide (ENA78), is an 8 kDa proinflammatory member of the CXC subfamily of chemokines. Its Glu-Leu-Arg (ELR) motif confers angiogenic properties and distinguishes it from ELR- CXC chemokines which are angiostatic. Human CXCL5 shares 57% amino acid (aa) sequence identity with mouse and rat CXCL5. Among other human ELR+ chemokines, it shares 77% aa sequence identity with CXCL6/GCP2 and 35%‑51% with CXCL1/GRO alpha, CXCL2/GRO beta, CXCL3/GRO gamma, CXCL7/NAP2, and CXCL8/IL8. Inflammatory stimulation upregulates CXCL5 production in multiple hematopoietic cell types, fibroblasts, endothelial cells, and vascular smooth muscle cells. In vivo, CXCL5 is elevated at sites of inflammation and pulmonary fibrosis where it promotes neutrophil infiltration and activation as well as angiogenesis. Its upregulation contributes to increased vascularization, tumor growth, and metastasis in many cancers. Full length CXCL5 (78 aa) is trimmed at the N-terminal end by Cathepsin G and chymotrypsin to ENA74 (74 aa) and ENA70 (70 aa), with the shortened forms showing increased potency relative to full length CXCL5. CXCL5 exerts its effects primarily through interactions with CXCR2. It also binds DARC, a decoy chemokine receptor which can limit CXCR2-mediated responses.
Product Datasheets
Citation for Human CXCL5/ENA-78 Antibody
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
1 Citation: Showing 1 - 1
-
Secretome of apoptotic peripheral blood cells (APOSEC) confers cytoprotection to cardiomyocytes and inhibits tissue remodelling after acute myocardial infarction: a preclinical study
Authors: Michael Lichtenauer, Michael Mildner, Konrad Hoetzenecker, Matthias Zimmermann, Bruno Karl Podesser, Wolfgang Sipos et al.
Basic Research in Cardiology
FAQs
No product specific FAQs exist for this product, however you may
View all Antibody FAQsReviews for Human CXCL5/ENA-78 Antibody
There are currently no reviews for this product. Be the first to review Human CXCL5/ENA-78 Antibody and earn rewards!
Have you used Human CXCL5/ENA-78 Antibody?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image